Home Sectors Healthcare Valuation Now: Mednax (NYSE: MD)

Valuation Now: Mednax (NYSE: MD)


Mednax is in the health care providers industry and is part of the healthcare sector. The company CEO is Roger J. Medel. Mednax Inc is a provider of physician services that are newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. Anesthesiology and Neonatology and other pediatric subspecialties generate more income.

Previous Intraday Trading Performance:

The MD stock showed a previous change of 0.04% with an open at 46.26 and a close of 46.43. It reached an intraday high of 46.84 and a low of 46.26.

Business Wire:  Surgical Directions Names Dr. Katherine Grichnik Medical Director and Vice President of Clinical Development


The stock has a market cap of $4.1b with 89.3m shares outstanding, of which the float is 86.8m shares. Trading volume reached 419,006 shares compared to its average volume of 701,998 shares. Based on the current average volume and close price, the trading liquidity is good.

Historical Trading Performance:

Over the last five trading days, Mednax shares returned 0.17% and in the past 30 trading days it returned -1.44%. Over three months, it changed 5.50%. In one year it has changed 9.04% and within that year its 52-week high was 63.04 and its 52-week low was 40.56. MD stock is 14.47% above its 52 Week Low.

Our calculations show a 200 day moving average of 49.52 and a 50 day moving average of 46.93. Currently MD stock is trading -6.24% below its 200 day moving average and may not be a good opportunity to buy as it may continue to trend down.

Business Wire:  Surgical Directions Names Dr. Katherine Grichnik Medical Director and Vice President of Clinical Development


The last annual fiscal EPS for the company was reported at 3.46 that ended on 31st of December 2017, which according to the previous close, that is a PE of 13.42. Based on 8 analyst estimates, the consensus EPS for the next quarter is 0.91. The TTM EPS is 3.44, which comes to a TTM PE of 13.50. Historically, the PE high was 35.70 and the PE low was 11.60. If the stock reached its PE low, that would represent a price of 39.90, which is a decrease of -14.07%.

The following are the last four quarter reported earnings per share:
06-30-2018:  0.99
03-31-2018:  0.81
12-31-2017:  0.82
09-30-2017:  0.82

Base on our calculations, the intrinsic value per share is 93.59, which means it is possibly undervalued and has a margin of safety of 50.39%

Indicators to Watch:

Short-interest is 2,185,045, which is 2.45% of shares outstanding. The short-interest ratio or days-to-cover ratio is 3.93. This stock has some short interest, but it may be normal and no cause for concern if long the position.

The current calculated beta is 0.17

SeekingAlpha:  U.S. Dividend Stocks On Discount – September 2018

Fundamental Indicators:

Based on last reported financials, the company’s return on equity is 11.33%, return on assets is 6.05%, profit margin is 10.24%, price-to-sales is 1.52 and price-to-book is 1.30.

Company Scores:

All scores are out of six:
 5  :Valuation Score
 3  :Past Performance Score
 3  :Financial Strength Score
 1  :Future Growth Score
 0  :Dividend Score
 3  :Overall Score

John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.